{"id":1230,"date":"2019-10-24T19:31:17","date_gmt":"2019-10-24T19:31:17","guid":{"rendered":"http:\/\/chooselife.co.uk\/?p=1230"},"modified":"2019-10-24T19:31:17","modified_gmt":"2019-10-24T19:31:17","slug":"omega-3-fatty-acids-for-the-management-of-hypertriglyceridemia-a-science-advisory-from-the-american-heart-association","status":"publish","type":"post","link":"https:\/\/chooselife.co.uk\/index.php\/2019\/10\/24\/omega-3-fatty-acids-for-the-management-of-hypertriglyceridemia-a-science-advisory-from-the-american-heart-association\/","title":{"rendered":"Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association"},"content":{"rendered":"\n

Ann C. Skulas-Ray<\/a>,\u00a0Peter W.F. Wilson<\/a>,\u00a0William S. Harris<\/a>,\u00a0Eliot A. Brinton<\/a>,\u00a0Penny M. Kris-Etherton<\/a>,\u00a0Chesney K. Richter<\/a>,\u00a0Terry A. Jacobson<\/a>,\u00a0Mary B. Engler<\/a>,\u00a0Michael Miller<\/a>,\u00a0Jennifer G. Robinson<\/a>,\u00a0Conrad B. Blum<\/a>,\u00a0Delfin Rodriguez-Leyva<\/a>,\u00a0Sarah D. de Ferranti<\/a>,\u00a0Francine K. Welty<\/a>,\u00a0and On behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology<\/a><\/p>\n\n\n\n

Originally published<\/strong> : 19 Aug 2019 https:\/\/doi.org\/10.1161\/CIR.0000000000000709<\/a><\/p>\n\n\n\n

Summary and Conclusions<\/h3>\n\n\n\n

Prescription n-3 FAs at the FDA-approved dose of 4 g\/d are safe and generally well tolerated. At this dose, triglyceride lowering of \u226530% has been reported in clinical trials of subjects with VHTG (triglycerides \u2265500 mg\/dL), in whom these agents are FDA approved.<\/p>\n\n\n\n

In VHTG, the goal of therapy is to reduce triglyceride levels to <500 mg\/dL and to lessen the risk of pancreatitis, although this may not be achieved with n-3 FA monotherapy, so additional triglyceride-lowering pharmacological treatment may be indicated. In the context of HTG (triglycerides, 200\u2013499 mg\/dL), 4 g\/d prescription n-3 FA effectively lowers triglycerides by \u224820% to 30% and does not significantly increase LDL-C.<\/p>\n\n\n\n

In all patients, established recommendations for diet and lifestyle should also be followed.11<\/a><\/sup>\u00a0In the largest studies of 4 g\/d EPA+DHA or EPA-only as adjuncts to statin therapy, non\u2013HDL-C and apo B were modestly decreased, suggesting reductions in total atherogenic lipoproteins. <\/p>\n\n\n\n

Use of n-3 FA may be accompanied by mild gastrointestinal complaints (such as \u201cfishy burps\u201d or nausea), but taking n-3 FA with meals may reduce gastrointestinal side effects and improve absorption of O3AEE and IPE. In clinical trials completed to date, <5% of subjects have discontinued omega-3 agents because of side effects. <\/p>\n\n\n\n

The triglyceride-lowering efficacy and generally excellent safety and tolerability of n-3 FAs make them valuable tools for healthcare providers. <\/strong>The use of n-3 FAs (4 g\/d) for improving ASCVD risk in patients with HTG is supported by a 25% reduction in major adverse cardiovascular end points in REDUCE-IT, a randomized placebo-controlled trial of EPA-only in high-risk patients on statin therapy. <\/p>\n\n\n\n

Results from the STRENGTH trial, a randomized placebo-controlled cardiovascular outcomes trial of 4 g\/d prescription EPA+DHA in patients with HTG and low HDL-C on statins, are anticipated in 2020. We conclude that prescription n-3 FAs, whether EPA+DHA or EPA-only, at a dose of 4 g\/d, are clinically useful for reducing triglycerides, after any underlying causes are addressed and diet and lifestyle strategies are implemented, either as monotherapy or as an adjunct to other triglyceride-lowering therapies\u00a0<\/strong><\/p>\n\n\n\n

Full : https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000709<\/a> <\/p>\n\n\n\n

ChooseLife<\/strong> Notes : It is well established that EPA and DHA are both readily created by ALA, so similar results should be expected from Flax Oil.<\/p>\n","protected":false},"excerpt":{"rendered":"

Ann C. Skulas-Ray,\u00a0Peter W.F. Wilson,\u00a0William S. Harris,\u00a0Eliot A. Brinton,\u00a0Penny M. Kris-Etherton,\u00a0Chesney K. Richter,\u00a0Terry A. Jacobson,\u00a0Mary B. Engler,\u00a0Michael Miller,\u00a0Jennifer G. Robinson,\u00a0Conrad B. Blum,\u00a0Delfin Rodriguez-Leyva,\u00a0Sarah D. de Ferranti,\u00a0Francine K. Welty,\u00a0and On behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; … <\/p>\n

Continue reading “Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[8],"tags":[],"_links":{"self":[{"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/posts\/1230"}],"collection":[{"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/comments?post=1230"}],"version-history":[{"count":1,"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/posts\/1230\/revisions"}],"predecessor-version":[{"id":1231,"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/posts\/1230\/revisions\/1231"}],"wp:attachment":[{"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/media?parent=1230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/categories?post=1230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chooselife.co.uk\/index.php\/wp-json\/wp\/v2\/tags?post=1230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}